B of A Securities Upgrades bluebird bio to Buy, Raises Price Target to $10
Portfolio Pulse from richadhand@benzinga.com
B of A Securities analyst Jason Gerberry has upgraded bluebird bio (NASDAQ:BLUE) from Neutral to Buy and raised the price target from $6 to $10.
July 19, 2023 | 10:19 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
bluebird bio's stock has been upgraded from Neutral to Buy by B of A Securities, with a raised price target from $6 to $10.
The upgrade from Neutral to Buy and the increase in price target by B of A Securities indicates a positive outlook for bluebird bio. This could lead to increased investor interest and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100